GlassScriptPhysician profile
Annapurna Bhat
NPI 1073608899
$2,877.29
in general payments reported to CMS, 2019-2025
28 companies · $181 in 2025
The $181 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $441 · 2021: $432 · 2022: $538 · 2023: $375 · 2024: $375 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $930.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $790.26 | 2019-2025 | Rinvoq |
| Ucb, INC. | $430.04 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $319.93 | 2019-2024 | Trelegy Ellipta, Arexvy, Benlysta |
| Sunovion Pharmaceuticals INC. | $297.38 | 2019-2021 | |
| Janssen Biotech, INC. | $110.67 | 2019-2024 | Tremfya |
| Mylan Specialty L.P. | $108.17 | 2019-2024 | Yupelri |
| Amgen INC. | $84.81 | 2019-2024 | Evenity, Otezla, Repatha |
| Pfizer INC. | $78.00 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $67.61 | 2020-2024 | Farxiga |
| Scilex Pharmaceuticals INC. | $67.45 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $66.91 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $56.92 | 2020-2024 | Orencia |
| Novo Nordisk INC | $40.96 | 2022-2023 | Rybelsus, Ozempic |
| Hikma Pharmaceuticals USA | $40.20 | 2019 | |
| Horizon Therapeutics Plc | $39.53 | 2019-2023 | Krystexxa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $38.01 | 2021-2025 | Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.82 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.33 | 2019 | |
| Edwards Lifesciences Corporation | $23.17 | 2021 | |
| Medtronic, INC. | $21.55 | 2025 | Venaseal |
| Shire North American Group INC | $20.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $20.00 | 2021 | |
| Genzyme Corporation | $19.03 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $18.88 | 2022 | |
| Viatris Specialty LLC | $17.87 | 2025 | Yupelri |
| Orexo US, INC. | $17.49 | 2019 | |
| Inogen, INC. | $15.01 | 2022 | |
| Eisai INC. | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annapurna Bhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.